Trial Profile

A Phase I/II Safety, Dose Finding and Feasibility Trial of MB-CART2019.1 in Patients With Relapsed or Resistant B-NHL

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 30 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zamtocabtagene autoleucel (Primary)
Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
Focus Adverse reactions; First in man
Sponsors Miltenyi Biotec GmbH

Most Recent Events

19 Jul 2024 Status changed from active, no longer recruiting to completed.
13 Dec 2022 Results from Phase I Trial in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma presented at the 64th American Society of Hematology Annual Meeting and Exposition
17 Jun 2022 Results presented at the 27th Congress of the European Haematology Association

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com